The U.S. National Institutes of Health said Wednesday it has launched a midterm study to determine the risk of allergic reactions to the Covid-19 vaccine developed by Moderna and Pfizer.
Many cases of allergies, including severe episodes called anaphylaxis, have been reported in the United States following injections of Pfizer / Biotech and Modern Shots.
In January, the US Centers for Disease Control and Prevention said allergic reactions were occurring at a rate of 11.1 per million vaccines.
The study, funded by the National Institute of Allergy and Infectious Diseases, will enroll 3,400 adults between the ages of 18 and 69, with approximately 60% of participants having severe allergic reactions to food, insect bites, or immunotherapy. Have a history of.
The goal of the trial is to reach the proportion of participants who have a systemic allergic reaction within 90 minutes of the injection.
The agency expects the data to be reported later this summer.
About Pfizer vaccines
The Pfizer Biotech Covid-19 vaccine is a messenger RNA (mRNA) vaccine that contains synthetic, or chemically prepared, and enzyme-produced components from naturally occurring substances such as proteins. The vaccine does not contain any live virus.
Its inactive substances include potassium chloride, monobasic potassium, phosphate, sodium chloride, dibasic sodium phosphate dehydrate, and sucrose, as well as a few other ingredients.
About Moderna vaccine
The Moderna COVID-19 vaccine is an mRNA vaccine against covid-19 encoding for the precision formulation of the spike (S) protein, developed by the National Institute of Allergy and Infectious Diseases (NIAID) Was made by. Vaccine Research Center.
The first clinical batch, funded by the Coalition for Epidemic Preparation Innovations, was completed on February 7, 2020, and underwent analytical testing; It was sent to the National Institutes of Health (NIH) on February 24, 2020, 42 days after the selection process.